Sagimet Biosciences Inc (NASDAQ:SGMT) has a beta value of 2.57 and has seen 1.13 million shares traded in the recent trading session. The company, currently valued at $179.76M, closed the recent trade at $5.86 per share which meant it lost -$0.92 on the day or -13.57% during that session. The SGMT stock price is -253.41% off its 52-week high price of $20.71 and 59.22% above the 52-week low of $2.39. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.06 million shares traded. The 3-month trading volume is 826.88K shares.
The consensus among analysts is that Sagimet Biosciences Inc (SGMT) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.63.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sporting -13.57% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMT stock price touched $5.86 or saw a rise of 20.6%. Year-to-date, Sagimet Biosciences Inc shares have moved 30.22%, while the 5-day performance has seen it change 24.15%. Over the past 30 days, the shares of Sagimet Biosciences Inc (NASDAQ:SGMT) have changed 25.75%. Short interest in the company has seen 4.17 million shares shorted with days to cover at 1.37.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 2.33% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -2.39% off the targeted high while a plunge would see the stock gain -2.39% from the levels at last check today..
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Figures show that Sagimet Biosciences Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 87.22% over the past 6 months, with this year growth rate of 39.47%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be -100.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.23% over the past 5 years.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders own 14.11% of the company shares, while shares held by institutions stand at 66.94% with a share float percentage of 77.94%. Investors are also buoyed by the number of investors in a company, with Sagimet Biosciences Inc having a total of 81.0 institutions that hold shares in the company.
